UK: NHS to Offer Wegovy to 1.2M Heart Patients

Narrative A

Wegovy is a genuine breakthrough for the 1.2 million people in England living with cardiovascular disease, which will cut their risk of a heart attack and stroke by 20%, as the SELECT trial has already proved. As a result, expanding NHS access to semaglutide is a cost-effective decision that will save lives when used with existing treatment options.